Investor Backing & Capital Strength:
Significant late-stage financing, including an $88M Series C (April 2024) and a $150M Series D (March 2026) at a reported ~$3B valuation, is presented as fuel for continued scale. These rounds are explicitly tied to expanding product capabilities, the provider network, and payer/employer channels.
Strategic Partnerships:
Expanded collaborations are highlighted, including a June 2026 research partnership with Stanford and broad access via 125+ insurer relationships, with added employer and health‑system programs (e.g., EAP‑to‑insurance continuity, Amazon, Circle Medical). These linkages signal deeper distribution and credibility across stakeholders.
Market Expansion:
Operational reach appears to be widening through national payer coverage (including Medicare/Medicaid), employer routes, and health‑system integrations alongside a provider network cited around 26,000. Utilization markers such as 7M visits in 2025 and active hiring/office expansion indicate scaling across markets.
